Revelation Biosciences Past Earnings Performance
Past criteria checks 0/6
Revelation Biosciences has been growing earnings at an average annual rate of 53.7%, while the Biotechs industry saw earnings growing at 11.7% annually.
Key information
53.7%
Earnings growth rate
99.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -1.8% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revelation Biosciences surges 46% on licensing deal with Vanderbilt University
Oct 06Revelation Biosciences GAAP EPS of -$0.12
Aug 15Revelation Biosciences stock slides 47% on pricing $5M securities offering
Jul 26Revelation Biosciences: Therapeutics And Diagnostics For Respiratory Viral Infections
Mar 28Revenue & Expenses BreakdownBeta
How Revelation Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | 0 | 5 | 4 |
| 30 Sep 23 | 0 | 1 | 4 | 3 |
| 30 Jun 23 | 0 | 2 | 4 | 2 |
| 31 Mar 23 | 0 | 2 | 4 | 2 |
| 31 Dec 22 | 0 | -11 | 5 | 5 |
| 30 Sep 22 | 0 | -13 | 6 | 8 |
| 30 Jun 22 | 0 | -15 | 6 | 9 |
| 31 Mar 22 | 0 | -16 | 7 | 9 |
| 31 Dec 21 | 0 | -12 | 5 | 7 |
| 30 Sep 21 | 0 | -11 | 5 | 6 |
Quality Earnings: REVB is currently unprofitable.
Growing Profit Margin: REVB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if REVB's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare REVB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: REVB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.9%).
Return on Equity
High ROE: REVB has a negative Return on Equity (-1.81%), as it is currently unprofitable.